IDEXX Laboratories, Inc. (IDXX) Earnings: Q3 2026 Results and Next Report Date

The quarter ended September 30, 2026 and IDEXX Laboratories published the results on November 2, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• IDEXX does not report an adjusted EPS figure. It describes EPS growth on a comparable basis, which excludes currency changes and certain items; comparable EPS growth was 22% in the quarter against 18% as reported.
• IDEXX acquired CoVet, a maker of AI ambient listening and clinical workflow software for veterinary practices, on September 15, 2026 for about $250 million. Its revenue in the quarter was immaterial.

Source: IDEXX Laboratories Q3 2026 results, November 2, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How IDEXX Laboratories splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• IDEXX Laboratories's Companion Animal Group (CAG) revenue was $1.1 billion in Q3 2026, up 10% from $1.0 billion in Q3 2025, 92% of total revenue.
• IDEXX Laboratories's Water revenue was $58.8 million in Q3 2026, up 8% from $54.3 million in Q3 2025, 5% of total revenue.
• IDEXX Laboratories's Livestock, Poultry and Dairy (LPD) revenue was $34.8 million in Q3 2026, up 3% from $33.9 million in Q3 2025, 3% of total revenue.
• IDEXX Laboratories's Other revenue was $4.6 million in Q3 2026, up 2% from $4.5 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, IDEXX Laboratories said:

“The Company is updating its full year revenue growth guidance range to $4,741 million-$4,767 million, or reported growth of 10.1%-10.8%, an increase of $32 million at midpoint, including $5 million related to the recent CoVet acquisition.”

“The Company is increasing its outlook for organic revenue growth to 9.3%-10.0%, an increase of 0.6% at midpoint, reflecting operational performance.”

“The Company lowered its full year reported operating margin outlook to 32.1%-32.3%, bringing the projected full year operating profit margin expansion to 50-70 basis points as reported and on a comparable basis.”

“The Company updated its EPS outlook range to $14.96-$15.16, a $0.25 increase compared to prior guidance midpoint, reflecting 15% reported and 16% comparable growth.”

Source: IDEXX Laboratories Q3 2026 release, Nov 2, 2026.

This is the company's own guidance as of Nov 2, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the IDXX forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS, each as first reported in that quarter's release.

IDEXX Laboratories's next report is expected around February 1, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q3 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 2, 2026

IDEXX Laboratories' Q3 2026 revenue was $1,214 million, up 10% as reported and organic. The Companion Animal Group, which sells diagnostics and software to veterinary practices, brought in $1,116.0 million of it. Water testing added $58.8 million, up 8%, and Livestock, Poultry and Dairy $34.8 million, up 3%. (IDEXX Laboratories Q3 2026 release, Nov 2, 2026)

Most of CAG is recurring diagnostics revenue: $967.4 million, up 10.8% as reported and 11.0% organic. IDEXX VetLab consumables, used with IDEXX's in-clinic analyzers, grew 14.3% to $443.2 million and reference laboratory services grew 10.0% to $399.1 million. Rapid assay products rose 0.6% to $89.1 million, with higher prices largely offset by lower volumes. (IDEXX Laboratories Q3 2026 release, Nov 2, 2026; IDEXX Laboratories Form 10-Q, Q3 2026, Nov 2, 2026)

The 10-Q attributes consumables growth to higher volumes and higher realized prices, helped by 11% growth in the installed base of premium instruments. IDEXX placed over 1,900 inVue Dx analyzers in the quarter, bringing that installed base to nearly 11,000. Capital instrument revenue was flat at $51.5 million because higher placements were offset by lower price realization from program pricing. (IDEXX Laboratories Q3 2026 release, Nov 2, 2026; IDEXX Laboratories Form 10-Q, Q3 2026, Nov 2, 2026)

By geography, U.S. revenue was $766.6 million, up 8.7%, and international revenue $447.7 million, up 11.9% as reported and 12.4% organic. International CAG Diagnostics recurring revenue grew 13.6% organic against 9.6% in the U.S. IDEXX had no customer above 10% of consolidated revenue in 2025. (IDEXX Laboratories Q3 2026 release, Nov 2, 2026; IDEXX Laboratories Form 10-K, 2025, Feb 20, 2026)

IDEXX Laboratories' diluted EPS was $4.01, up 18% from $3.40, and up 22% on a comparable basis. IDEXX does not publish an adjusted EPS figure. It said EPS included a $0.03 per share non-operating gain on an equity investment, $0.01 in tax benefits from share-based compensation and a $0.04 benefit from currency and absorbed acquisition impacts. (IDEXX Laboratories Q3 2026 release, Nov 2, 2026)

Gross margin rose 110 basis points to 62.9% and operating margin 100 basis points to 33.1%, on recurring revenue volume gains, productivity and net price realization. Operating expenses rose 10%, including acquisition transaction-related costs. The effective tax rate was 20.6%, against 20.4%, on lower share-based compensation tax benefits and higher international taxes. (IDEXX Laboratories Q3 2026 release, Nov 2, 2026; IDEXX Laboratories Form 10-Q, Q3 2026, Nov 2, 2026)

Diluted shares fell to 79.0 million from 80.7 million. IDEXX repurchased 199 thousand shares in the open market in Q3 for $111.8 million, at an average $563.04, and $804.7 million over the first nine months. (IDEXX Laboratories Q3 2026 release, Nov 2, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

IDEXX Laboratories gives a detailed full-year outlook in its release and raised it with Q3 2026 results. It now expects 2026 revenue of $4,741 million to $4,767 million, up from $4,700 million to $4,745 million, including $5 million from CoVet, with organic growth of 9.3% to 10.0%. The EPS outlook rose to $14.96 to $15.16 from $14.69 to $14.94. (IDEXX Laboratories Q3 2026 release, Nov 2, 2026)

IDEXX lowered its reported operating margin outlook to 32.1% to 32.3% from 32.3% to 32.5%, which it said includes acquisition-related impacts. The outlook assumes an effective tax rate of about 20.5%, about $0.25 of EPS benefit from currency and capital expenditures of about $160 million. (IDEXX Laboratories Q3 2026 release, Nov 2, 2026)

A consensus figure is the average of the models published by the analysts who cover IDEXX Laboratories, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones IDEXX Laboratories's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning IDXX is on is IDXX a buy or a sell?, what analysts expect next is on the IDXX forecast, and what the company does is on the IDEXX Laboratories, Inc. (IDXX) stock page.

Every number on this page can be traced to a document IDEXX Laboratories published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.